Product logins

Find logins to all Clarivate products below.


Crohn’s Disease – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence of Crohn’s disease for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s Crohn’s disease forecast answers the following questions:

  • Of all people with Crohn’s disease, how many in each country have been formally diagnosed?
  • Of all people diagnosed with Crohn’s disease, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Crohn’s disease over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following Crohn’s disease subpopulations:

  • Diagnosed prevalent cases.
  • Diagnosed incident cases.
  • Diagnosed prevalent cases by disease behaviour.
  • Diagnosed prevalent cases by disease location.
  • Diagnosed prevalent cases by disease severity.
  • Diagnosed prevalent cases by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…